- ImmuPharma issued an update on its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus.
- Key highlights included:
- 200 patients were successfully recruited and randomised (dosed)
- all patients in the study have passed the 9 months stage
- 116 patients (58%) have completed the full 12 months of the study
Northland Capital analyst this morning said: “Lupuzor is progressing well through its pivotal Phase III trial. The drug continues to demonstrate a strong safety profile. The study is on track to report top line results in Q1-2018. Should Lupuzor successfully meet the trial endpoints, we estimate that ImmuPharma’s shares would significantly rerate to the upside.”